During the past decade, Sarcoma Oncology Center conducted 83 clinical trials. In the 10-year time frame, 83 clinical trials started and 32 clinical trials were completed, i.e. on average, 38.6% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 22 clinical trials were completed. i.e. 62.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sarcoma Oncology Center" #1 sponsor was "ImmunityBio, Inc." with 6 trials, followed by "Sarcoma Alliance for Research through Collaboration" with 6 trials sponsored, "Sarcoma Oncology Research Center, LLC" with 5 trials sponsored, "Amgen" with 4 trials sponsored and "Hoffmann-La Roche" with 4 trials sponsored. Other sponsors include 90 different institutions and companies that sponsored additional 71 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sarcoma Oncology Center" #1 collaborator was "Bristol-Myers Squibb" with 3 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator, "National Cancer Institute (NCI)" with 3 trials as a collaborator, "Novartis" with 2 trials as a collaborator and "Sarcoma Alliance for Research through Collaboration" with 2 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "Sarcoma Oncology Center" are "Sarcoma" (14 trials), "Soft Tissue Sarcoma" (11 trials), "Advanced Solid Tumors" (9 trials), "Pancreatic Cancer" (8 trials) and "Breast Cancer" (7 trials). Many other conditions were trialed in "Sarcoma Oncology Center" in a lesser frequency.

Most popular intervention types in "Sarcoma Oncology Center" are "Drug" (110 trials), "Biological" (14 trials), "Other" (5 trials), "Genetic" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Doxorubicin" (6 trials), "Gemcitabine" (5 trials), "Nivolumab" (5 trials) and "aldoxorubicin" (4 trials). Other intervention names were less common.

The vast majority of trials in "Sarcoma Oncology Center" are 118 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Sarcoma Oncology Center". undefined are not yet recruiting, 30 are recruiting, 14 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 54 completed trials in Sarcoma Oncology Center, undefined suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Sarcoma Oncology Center, 52 "Phase 1" clinical trials were conducted, 74 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".